Sionna Therapeutics (NASDAQ:SION) Stock Rating Lowered by Wall Street Zen

Sionna Therapeutics (NASDAQ:SION) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

Other research analysts have also issued reports about the company. JonesTrading lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Citigroup lowered shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Wednesday, August 5th. Freedom Capital cut shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Finally, Wedbush downgraded shares of Sionna Therapeutics from an “outperform” rating to a “neutral” rating and set a $5.00 price objective for the company. in a report on Monday, August 10th. One research analyst has rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Sionna Therapeutics presently has an average rating of “Hold” and an average price target of $42.22.

Sionna Therapeutics Price Performance

Shares of SION opened at $6.46 on Friday. The stock’s 50-day moving average price is $39.18 and its 200 day moving average price is $39.16. The firm has a market capitalization of $292.06 million, a price-to-earnings ratio of -2.96 and a beta of 1.32. Sionna Therapeutics has a 12-month low of $4.01 and a 12-month high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). Equities research analysts expect that Sionna Therapeutics will post -2.55 EPS for the current year.

Insider Buying and Selling

In related news, Director Orbimed Advisors Llc sold 115,844 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. This trade represents a 4.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 115,844 shares of the business’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total value of $5,270,902.00. Following the completion of the sale, the director directly owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This represents a 4.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 403,726 shares of company stock valued at $18,259,354. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Deutsche Bank AG increased its position in shares of Sionna Therapeutics by 4.5% during the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock worth $413,000 after purchasing an additional 433 shares in the last quarter. Bank of America Corp DE lifted its holdings in Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after purchasing an additional 529 shares during the last quarter. MetLife Investment Management LLC boosted its position in Sionna Therapeutics by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock valued at $352,000 after buying an additional 532 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after buying an additional 619 shares in the last quarter. Finally, State of Wyoming bought a new stake in Sionna Therapeutics during the second quarter worth about $35,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.